Business Context and Reporting Period
Company: Kimberly-Clark Corporation
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Third quarter and nine months ended September 30, 2002
Business Overview: The Corporation operates in three primary segments: Personal Care (diapers, feminine care), Consumer Tissue (facial/bathroom tissue, paper towels), and Business-to-Business (health care products, away-from-home tissue). As of November 4, 2002, there were 514,346,580 shares of common stock outstanding.
Key Financial Metrics
| Metric (Millions, except per share) | Q3 2002 | Q3 2001 | 9M 2002 | 9M 2001 |
|---|---|---|---|---|
| Net Sales | $3,486.7 | $3,373.7 | $10,226.5 | $9,942.2 |
| Operating Profit | $644.8 | $629.1 | $1,934.0 | $1,850.8 |
| Net Income | $441.2 | $419.4 | $1,305.0 | $1,268.2 |
| Diluted EPS | $0.85 | $0.79 | $2.50 | $2.37 |
| Cash from Operations (9M) | $1,874.9 | $1,665.0 | ||
| Cash and Equivalents (Sep 30) | $489.2 | $405.2 (Dec 31, 2001) | ||
| Total Debt (Sep 30) | $3,779.4 | $3,660.1 (Dec 31, 2001) |
Note: Total Debt calculated as Debt payable within one year ($933.8M) plus Long-term debt ($2,845.6M). Net debt (total debt less cash) was $3.8 billion.
Material Changes vs. Prior Period
- Revenue Growth: Consolidated net sales increased 3.3% in Q3 2002 and 2.9% for the nine-month period compared to 2001. Worldwide sales volumes rose 5% in Q3, driven by Consumer Tissue and Health Care products.
- Profitability: Net income increased 5.2% in Q3 and 2.9% for the nine-month period. Operating profit increased 2.5% in Q3 before unusual items.
- Accounting Change: The Company adopted SFAS 142 on January 1, 2002, discontinuing goodwill amortization. This eliminated $22.7 million in Q3 2001 and $67.0 million in the first nine months of 2001 from expenses, improving reported margins.
- Segment Performance:
- Personal Care: Sales declined 1.3% in Q3 due to competitive pricing in North America and Europe, though volumes rose 2%.
- Consumer Tissue: Sales rose 8.6% in Q3, driven by volume increases of nearly 10%.
- Business-to-Business: Sales increased 3.6% in Q3, led by an 8% volume gain in health care products.
- Unusual Items: Q3 2002 included $11.6 million in charges (2 cents per share) related to streamlining operations in Latin America/Europe and a Colombian tax levy. Nine-month charges totaled $62.1 million.
Guidance, Outlook, and Risks
- 2002 Outlook: Management expects full-year 2002 earnings per share before unusual items to be in the range of $3.42 to $3.46, representing mid-single-digit growth. This is slightly below analyst estimates ($3.50–$3.56) due to increased competitive activity in diapers/training pants and currency fluctuations in Latin America.
- Q4 Expectations: Q4 earnings per share before unusual items are expected to be similar to Q3, excluding incremental costs of 2 to 3 cents per share related to package count changes and new product start-up costs.
- Capital Spending: Guidance for 2002 capital spending was revised to a range of $850 million to $900 million (previously $900 million).
- Liquidity: The Company maintains a net debt to capital ratio of 38.0%, within its target range of 35% to 45%. Management believes cash flow and debt capacity are adequate for future needs.
- Risks:
- Competition: Aggressive promotional activity in North America and Europe is pressuring net selling prices.
- Currency: Weak economies and currency devaluations in Latin America (specifically Argentina) negatively impacted sales.
- Legal/Environmental: The Company is a potentially responsible party at various waste disposal sites, though management does not expect a material adverse effect. The Anne Meader litigation was settled for a nonmaterial amount.
Investor Verification Checklist
- Goodwill Amortization Impact: Verify the pro-forma impact of SFAS 142 adoption on year-over-year comparisons, as the elimination of amortization significantly boosted 2002 reported earnings relative to 2001.
- Unusual Items Exclusion: Review operating profit "before unusual items" to assess core operational performance, as $11.6M in Q3 charges obscured underlying segment results.
- Latin America Exposure: Assess the specific impact of the Argentine economic crisis and Colombian tax levies on the Personal Care segment's long-term growth trajectory.
- Promotional Spending: Monitor the sustainability of sales volume growth given the 4% decline in net selling prices in North America due to competitive promotions.
- Debt Levels: Confirm the stability of the net debt position ($3.8 billion) amidst increased capital spending and share repurchases ($464 million in the first nine months).